Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis.
Atrophy
IgG4-related autoimmune pancreatitis
Relapse
Swelling
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
06
12
2021
accepted:
31
01
2022
revised:
26
01
2022
pubmed:
18
2
2022
medline:
24
5
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
This study aims to clarify the relationship between the changes of pancreatic size after glucocorticoid (GC) therapy and relapse in IgG4-related autoimmune pancreatitis (AIP). We prospectively enrolled 205 newly diagnosed IgG4-related AIP patients. 145 patients were followed up for more than 3 years. These patients were divided into three groups according to the changes of pancreatic size after treatment of 6 months: pancreatic swelling, normal size, and pancreatic atrophy. Baseline clinical and laboratory parameters were compared among three groups. Kaplan-Meier survival analysis was performed in the 134 patients based on GC therapy. Besides, Cox regression analysis and logistic regression analysis were performed to identify risk factors associated with relapse and the potential variables affecting changes of pancreatic size after treatment. Age at diagnosis, white blood cell count, and serum IgG1 level at baseline were significantly different among the three groups. After treatment of 6 months, the pancreas of most patients (n = 81, 55.9%) could return to normal size, while persistent pancreatic swelling was found in 24.1% patients (n = 35), and atrophy was observed in 20.0% of the patients (n = 29). Kaplan-Meier survival analysis presented patients with pancreatic swelling after 6 months of GC therapy were more likely to relapse in the follow-up of 3 years. Persistent pancreatic swelling after treatment and salivary gland involvement at baseline were independent risk variables associated with relapse in IgG4-related AIP patients, while GC-based therapy was a protective factor of relapse. Logistic regression analysis revealed that older age at diagnosis was associated with pancreatic atrophy and higher baseline serum IgG1 level was associated with pancreatic swelling after treatment of 6 months. Patients with persistent pancreatic swelling after GC-based therapy of 6 months were more likely to relapse in the follow-up of 3 years. Older age at diagnosis and higher baseline serum IgG1 level were potential variables associated with pancreatic atrophy or swelling after treatment of 6 months. Key Points • Patients with persistent pancreatic swelling after glucocorticoid-based therapy were more likely to relapse in IgG4-related autoimmune pancreatitis. • Older age at diagnosis was associated with pancreatic atrophy after glucocorticoid-based therapy. • Higher baseline serum IgG1 level was associated pancreatic swelling after glucocorticoid-based therapy.
Identifiants
pubmed: 35175447
doi: 10.1007/s10067-022-06091-5
pii: 10.1007/s10067-022-06091-5
doi:
Substances chimiques
Glucocorticoids
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1709-1718Subventions
Organisme : National Natural Science Foundation of China
ID : 81771757
Organisme : National Natural Science Foundation of China
ID : 82071839
Informations de copyright
© 2022. International League of Associations for Rheumatology (ILAR).
Références
Kamisawa T, Takuma K, Egawa N, Tsuruta K, Sasaki T (2010) Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 7(7):401–409
doi: 10.1038/nrgastro.2010.81
Shimosegawa T, Chari ST, Frulloni L et al (2011) International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 40(3):352–358
doi: 10.1097/MPA.0b013e3182142fd2
Kuruma S, Kamisawa T, Kikuyama M et al (2019) Clinical characteristics of autoimmune pancreatitis with IgG4 related kidney disease. Adv Med Sci 64(2):246–251
doi: 10.1016/j.advms.2018.12.005
Naitoh I, Nakazawa T, Ohara H et al (2010) Clinical significance of extrapancreatic lesions in autoimmune pancreatitis. Pancreas 39(1):e1-5
doi: 10.1097/MPA.0b013e3181bd64a1
Khandelwal A, Inoue D, Takahashi N (2020) Autoimmune pancreatitis: an update. Abdom Radiol (New York) 45(5):1359–1370
doi: 10.1007/s00261-019-02275-x
Dong Y, D’Onofrio M, Hocke M et al (2018) Autoimmune pancreatitis: imaging features. Endoscopic ultrasound 7(3):196–203
doi: 10.4103/eus.eus_23_17
Umehara H, Okazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22(1):21–30
doi: 10.3109/s10165-011-0571-z
Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 259408
Rehnitz C, Klauss M, Singer R et al (2011) Morphologic patterns of autoimmune pancreatitis in CT and MRI. Pancreatol: Off J Int Assoc Pancreatology (IAP) [et al] 11(2):240–51
doi: 10.1159/000327708
Vlachou PA, Khalili K, Jang HJ, Fischer S, Hirschfield GM, Kim TK (2011) Ig-related sclerosing disease autoimmune pancreatitis and extrapancreatic manifestations. Radiograph a Rev Publication Radiol Soc North Am Inc 31(5):1379–402
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N (2003) Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98(12):2694–2699
doi: 10.1111/j.1572-0241.2003.08775.x
Ishikawa T, Kawashima H, Ohno E et al (2020) Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study. Endoscopy 52(11):978–985
doi: 10.1055/a-1183-3583
Hirano K, Tada M, Isayama H et al (2013) High alcohol consumption increases the risk of pancreatic stone formation and pancreatic atrophy in autoimmune pancreatitis. Pancreas 42(3):502–505
doi: 10.1097/MPA.0b013e31826b3984
Masuda A, Shiomi H, Matsuda T et al (2014) The relationship between pancreatic atrophy after steroid therapy and diabetes mellitus in patients. Pancreatol : Off J Int Assoc Pancreatol (IAP) [et al] 14(5):361–5
doi: 10.1016/j.pan.2014.07.005
Yamada Y, Masuda A, Sofue K et al (2020) Prediction of pancreatic atrophy after steroid therapy using equilibrium-phase contrast computed tomography imaging in autoimmune pancreatitis. JGH Open : Open Access J Gastroenterol Hepatol 4(4):677–683
doi: 10.1002/jgh3.12316
Yunyun F, Yu P, Panpan Z et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatol (Oxford) 58(1):52–60
doi: 10.1093/rheumatology/key227
Peng Y, Li JQ, Zhang PP et al (2019) Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med 286(5):542–552
doi: 10.1111/joim.12942
Zhang W, Stone JH (2019) Management of IgG4-related disease. Lancet Rheumatol 1(1):e55–e65
doi: 10.1016/S2665-9913(19)30017-7
Yamamoto M, Nojima M, Takahashi H et al (2015) Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatol (Oxford) 54(1):45–49
doi: 10.1093/rheumatology/keu228
Hart PA, Topazian MD, Witzig TE et al (2013) Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 62(11):1607–1615
doi: 10.1136/gutjnl-2012-302886
Crosara S, D’Onofrio M, De Robertis R et al (2014) Autoimmune pancreatitis: multimodality non-invasive imaging diagnosis. World J Gastroenterol 20(45):16881–16890
doi: 10.3748/wjg.v20.i45.16881
Kreel L, Sandin B (1973) Changes in pancreatic morphology associated with aging. Gut 14(12):962–970
doi: 10.1136/gut.14.12.962
Kubota K, Iida H, Fujisawa T et al (2007) Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 66(6):1142–1151
doi: 10.1016/j.gie.2007.06.059
Hirano K, Tada M, Isayama H et al (2007) Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 56(12):1719–1724
doi: 10.1136/gut.2006.115246
Maire F, Le Baleur Y, Rebours V et al (2011) Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol 106(1):151–156
doi: 10.1038/ajg.2010.314
Kamisawa T, Shimosegawa T, Okazaki K et al (2009) Standard steroid treatment for autoimmune pancreatitis. Gut 58(11):1504–1507
doi: 10.1136/gut.2008.172908
Shiokawa M, Kodama Y, Kuriyama K et al (2016) Pathogenicity of IgG in patients with IgG4-related disease. Gut 65(8):1322–1332
doi: 10.1136/gutjnl-2015-310336
Mizushima I, Yamada K, Fujii H et al (2012) Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis. Mod Rheumatol 22(6):859–870
doi: 10.3109/s10165-011-0589-2
Saeki T, Kawano M, Mizushima I et al (2013) The clinical course of patients with IgG4-related kidney disease. Kidney Int 84(4):826–833
doi: 10.1038/ki.2013.191
Raissian Y, Nasr SH, Larsen CP et al (2011) Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol 22(7):1343–1352
doi: 10.1681/ASN.2011010062
Mizushima I, Yamamoto M, Inoue D et al (2016) Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Res Ther 18(1):273
doi: 10.1186/s13075-016-1175-y